Edesa Biotech, Inc. (EDSA) Stock Price & Analysis
Edesa Biotech, Inc. (EDSA) fell 7.24% to USD 5.25 as of July 25, 2026 at 04:20 UTC, according to Nexqual real-time market data.
EDSA last closed at USD 5.66; the session ranged USD 5.25–5.89 on volume of 50,064 shares. Market capitalization is —, with a 52-week range of USD 0.72–20.32 (NCM). Source: Nexqual, July 25, 2026 at 04:20 UTC.
Key Statistics (as of July 25, 2026 at 04:20 UTC)
| Price | USD 5.25 |
|---|---|
| Change | ▼ 7.24% (down) |
| Previous Close | USD 5.66 |
| Open | USD 5.63 |
| Day Range | USD 5.25 – 5.89 |
| 52-Week Range | USD 0.72 – 20.32 |
| Volume | 50,064 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (EDSA)
Nexqual's technical model rates EDSA "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.14 (neutral) |
| vs SMA50 | Below (USD 7.65) |
| MACD | -0.55 (negative) |
Analyst Ratings (EDSA)
Wall Street analysts rate EDSA "None" based on 3 analysts, with a mean price target of USD 16.33 (range USD 9–21), per Nexqual as of July 25, 2026 at 04:20 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 16.33 |
| High Target | USD 21 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (EDSA)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.49 vs est -0.26 ▼ miss |
| 2025-12-31 | USD -0.28 vs est -0.45 ▲ beat |
| 2025-09-30 | USD -0.32 vs est -0.27 ▼ miss |
| 2025-06-30 | USD -0.25 vs est -0.26 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:20 UTC.
Financials & Fundamentals (EDSA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -81.16% |
| Current Ratio | 4.76 |
| Total Cash | $10.00M |
| Total Debt | $0 |
| Free Cash Flow | $-3.96M |
Source: Nexqual, July 25, 2026 at 04:20 UTC.
Financial Health Score (EDSA)
Nexqual rates Edesa Biotech, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 04:20 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $10M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$8M |
| Efficiency | Critical — ROE -81%, ROA -47.7% |
Ownership (EDSA)
| Insider Ownership | +18.66% |
|---|---|
| Institutional Ownership | +39.08% |
| Float | 4.86M |
| Short % of Float | +3.17% |
Source: Nexqual, July 25, 2026 at 04:20 UTC.
Leadership (EDSA)
Edesa Biotech, Inc. is led by Pardeep Nijhawan FRCPC (age 54), CEO, Company Secretary & Director, per Nexqual as of July 25, 2026 at 04:20 UTC.
| CEO, Company Secretary & Director | Pardeep Nijhawan FRCPC (age 54) |
|---|---|
| President | Michael J. Brooks (age 46) |
| Chief Financial Officer | Peter John Weiler M.B.A, M.Sc. (age 56) |
Major Backers & Investors (EDSA)
Notable institutional backers of Edesa Biotech, Inc. include Velan Capital Investment Management LP, Rubric Capital Management LP, Perceptive Advisors Llc, according to Nexqual as of July 25, 2026 at 04:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Velan Capital Investment Management LP | 8.59% |
| Rubric Capital Management LP | 7.14% |
| Perceptive Advisors Llc | 5.85% |
| Jane Street Group, LLC | 1.2% |
| Fidelity | 0.64% |
| Commonwealth Equity Services, LLC | 0.36% |
| Scientech Research LLC | 0.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.18% |
| Geode Capital | 0.8% |
| State Street | 0.39% |
Source: Nexqual, July 25, 2026 at 04:20 UTC.
From Edesa Biotech, Inc.'s Latest SEC 10-K Filing (filed 2025-12-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases.
- It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
- The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B.
- It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRVS | Corvus Pharmaceuticals, Inc. | USD 13.07 | ▼ 6.58% |
| SNOA | Sonoma Pharmaceuticals, Inc. | USD 1.14 | ▼ 1.72% |
| IMRN | Immuron Limited | USD 1.11 | ▼ 1.77% |
| ATHE | Alterity Therapeutics Limited | USD 4.54 | ▼ 3.4% |
| PHIO | Phio Pharmaceuticals Corp. | USD 1.04 | ▼ 1.89% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:20 UTC. This page is informational and not investment advice.